Missoula, Montana isn’t exactly where biotech tourists set their GPS, but that’s why FYR Bio feels like a spark in the dark. While the coasts chase buzzwords, this team is building a platform with bite. The EVO system isn’t window dressing; it’s a marriage of SPARCs chemistry and AI-driven multi-omics that pulls real disease signals from blood. Tumor fragments, brain-derived vesicles, protein whispers—most labs can’t even hear the conversation. FYR Bio captures it, cleans the noise, and translates it into insights that actually shift clinical decisions. That’s not promise, that’s precision.
The company just raised an $8 million Series A, led by The Sontag Innovation Fund and The Yuvaan Tiwari Foundation, with Two Bear Capital returning from their seed round. That’s not speculative capital; it’s belief forged in data. Investors don’t stack chips on long shots; they back founders who deliver. Chris Booth, PhD, CEO and co-founder, has been leading this since inception, pairing scientific depth with operational edge. Add in Claire Seibold steering software and analytics and Katie Havranek, PhD driving research, and you’ve got a roster built for scale, not a lucky streak.
The track record is already visible. When COVID hit, FYR Bio moved fast enough to land a state contract for high-throughput testing. After that, they inked a know-how agreement with Mayo Clinic to advance Parkinson’s biomarkers. And then there’s the glioma study: 100 percent specificity, 89 percent sensitivity, an AUC of 0.99. That’s not marketing confetti; it’s a diagnostic breakthrough hiding in plain sight.
The industry loves to promise liquid biopsy revolutions, but most platforms stall in the noise. SPARCs reagents give FYR Bio the leverage: cleaner EV capture, sharper signals, and AI pipelines that turn blood into a data-rich map. With CLIA certification locked and HIPAA compliance integrated, this is already clinical-grade. What comes next is scaling oncology biomarker panels, validating neurodegeneration assays, and building deeper partnerships with biopharma players who need accuracy more than they need headlines.
This $8 million round isn’t a lifeline; it’s an accelerant. Expanding the oncology portfolio. Pushing into neuro-oncology and neurodegeneration. Growing R&D and bioinformatics muscle. Prepping regulatory pathways so assays don’t just dazzle at conferences but actually show up in clinics. In a field addicted to disruption narratives, FYR Bio is doing the hard, quieter work of building tools that last.
The difference is simple. Competitors are still selling hope. FYR Bio is selling signal. And with this Series A, they’ve got the firepower to turn that signal into a standard.
